The estimated Net Worth of John H Tucker is at least 1.69 百万$ dollars as of 7 October 2022. Mr. Tucker owns over 42,250 units of scPharmaceuticals Inc stock worth over 455,873$ and over the last 7 years he sold SCPH stock worth over 0$. In addition, he makes 1,238,320$ as President、 Chief Executive Officer、 Principal Executive Officer、 Principal Financial Officer and Director at scPharmaceuticals Inc.
John has made over 4 trades of the scPharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 42,250 units of SCPH stock worth 215,898$ on 7 October 2022.
The largest trade he's ever made was exercising 42,250 units of scPharmaceuticals Inc stock on 7 October 2022 worth over 215,898$. On average, John trades about 8,292 units every 86 days since 2018. As of 7 October 2022 he still owns at least 89,212 units of scPharmaceuticals Inc stock.
You can see the complete history of Mr. Tucker stock trades at the bottom of the page.
John H. Tucker serves as President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Director of the Company. Mr. Tucker served as chief executive officer of Algal Scientific Corporation. Before Algal Scientific, from 2014 to 2016, Mr. Tucker served as chief executive officer of Alcresta, a developer of enzyme-based products for patients with acute and chronic diseases. Prior to Alcresta, from late 2013 to April 2014, Mr. Tucker worked at Nelson Bach U.S. Ltd., a natural healthcare products manufacturer, as chief executive officer of its North American business. Prior to that, he served as senior vice president and chief commercial officer of Incline Therapeutics, a hospital-focused specialty pharmaceutical company, from 2012 until the company was purchased by The Medicines Company in January 2013. Mr. Tucker continued in his role at The Medicines Company through the transition into late 2013. Mr. Tucker joined Incline from AMAG Pharmaceuticals, a pharmaceutical company developing products that treat adults with iron deficiency anemia, where he was senior vice president, Commercial Operations in 2012. Prior to AMAG Pharmaceuticals, from 2007 to 2011, Mr. Tucker served as president, U.S. Operations at Basilea Pharmaceuticals, a multinational specialty biopharmaceutical company. Prior to Basilea, from 2002 to 2007, Mr. Tucker was executive vice president, Sales and Marketing at Indevus Pharmaceuticals, a specialty pharmaceutical company. Mr. Tucker also previously served at ALZA, a global pharmaceutical company, and at Johnson & Johnson, including as senior director of trade relations, government sales and senior care. Mr. Tucker holds a B.A. from Plymouth State College and an M.B.A. from New Hampshire College.
As the President、 Chief Executive Officer、 Principal Executive Officer、 Principal Financial Officer and Director of scPharmaceuticals Inc, the total compensation of John Tucker at scPharmaceuticals Inc is 1,238,320$. There are no executives at scPharmaceuticals Inc getting paid more.
John Tucker is 57, he's been the President、 Chief Executive Officer、 Principal Executive Officer、 Principal Financial Officer and Director of scPharmaceuticals Inc since 2019. There are 7 older and 4 younger executives at scPharmaceuticals Inc. The oldest executive at scPharmaceuticals Inc is Leonard Schaeffer, 74, who is the Independent Director.
John's mailing address filed with the SEC is C/O SCPHARMACEUTICALS INC., 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA, 01803.
Over the last 7 years, insiders at scPharmaceuticals Inc have traded over 5,999,254$ worth of scPharmaceuticals Inc stock and bought 6,409,552 units worth 61,370,807$ . The most active insiders traders include Capital Management, L.P.Ra ...、Jonathan Silverstein、Advisors Llc Orbi Med Capit.... On average, scPharmaceuticals Inc executives and independent directors trade stock every 112 days with the average trade being worth of 1,808,281$. The most recent stock trade was executed by Leonard D Schaeffer on 26 August 2024, trading 11,347 units of SCPH stock currently worth 29,275$.
scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
scPharmaceuticals Inc executives and other stock owners filed with the SEC include: